BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Volpi CC, Pietrantonio F, Gloghini A, Fucà G, Giordano S, Corso S, Pruneri G, Antista M, Cremolini C, Fasano E, Saggio S, Faraci S, Di Bartolomeo M, de Braud F, Di Nicola M, Tagliabue E, Pupa SM, Castagnoli L. The landscape of d16HER2 splice variant expression across HER2-positive cancers. Sci Rep 2019;9:3545. [PMID: 30837627 DOI: 10.1038/s41598-019-40310-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang S, Zhao Y, Song Y, Qiao G, Di Y, Zhao J, Sun P, Zheng H, Huang H, Huang H. ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab. Front Oncol 2022;12:855308. [PMID: 35463314 DOI: 10.3389/fonc.2022.855308] [Reference Citation Analysis]
2 Veiga DFT, Nesta A, Zhao Y, Mays AD, Huynh R, Rossi R, Wu TC, Palucka K, Anczukow O, Beck CR, Banchereau J. A comprehensive long-read isoform analysis platform and sequencing resource for breast cancer. Sci Adv 2022;8:eabg6711. [PMID: 35044822 DOI: 10.1126/sciadv.abg6711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
3 Díaz-Rodríguez E, Gandullo-Sánchez L, Ocaña A, Pandiella A. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers (Basel) 2021;14:154. [PMID: 35008318 DOI: 10.3390/cancers14010154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Gao Z, Xu J, Wang Y, Wu J, Sun T. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant. Front Oncol 2021;11:715554. [PMID: 34722261 DOI: 10.3389/fonc.2021.715554] [Reference Citation Analysis]
5 Ebrahimie E, Rahimirad S, Tahsili M, Mohammadi-Dehcheshmeh M. Alternative RNA splicing in stem cells and cancer stem cells: Importance of transcript-based expression analysis. World J Stem Cells 2021; 13(10): 1394-1416 [PMID: 34786151 DOI: 10.4252/wjsc.v13.i10.1394] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Pupa SM, Ligorio F, Cancila V, Franceschini A, Tripodo C, Vernieri C, Castagnoli L. HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. Cancers (Basel) 2021;13:4778. [PMID: 34638263 DOI: 10.3390/cancers13194778] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
7 Mehterov N, Kazakova M, Sbirkov Y, Vladimirov B, Belev N, Yaneva G, Todorova K, Hayrabedyan S, Sarafian V. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy. Genes (Basel) 2021;12:1085. [PMID: 34356101 DOI: 10.3390/genes12071085] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Chen B, Xu X, Lin DD, Chen X, Xu YT, Liu X, Dong WG. KRT18 Modulates Alternative Splicing of Genes Involved in Proliferation and Apoptosis Processes in Both Gastric Cancer Cells and Clinical Samples. Front Genet 2021;12:635429. [PMID: 34290732 DOI: 10.3389/fgene.2021.635429] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Jiao XD, Liu K, Wu Y, Zhou XC, Qin BD, Ling Y, Liu J, He X, Du H, Xiang J, Zang YS. HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma. Oncologist 2021;26:717-21. [PMID: 33896090 DOI: 10.1002/onco.13799] [Reference Citation Analysis]
10 Hart V, Gautrey H, Kirby J, Tyson-Capper A. HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes. Oncotarget 2020;11:4338-57. [PMID: 33245725 DOI: 10.18632/oncotarget.27789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
11 Pellarin I, Belletti B, Baldassarre G. RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target. Med Res Rev 2021;41:586-615. [PMID: 33058230 DOI: 10.1002/med.21741] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Siena S, Marsoni S, Sartore-Bianchi A. Breaking Barriers in HER2+ Cancers. Cancer Cell 2020;38:317-9. [PMID: 32857948 DOI: 10.1016/j.ccell.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Volpari T, De Santis F, Bracken AP, Pupa SM, Buschbeck M, Wegner A, Di Cosimo S, Lisanti MP, Dotti G, Massaia M, Pruneri G, Anichini A, Fortunato O, De Braud F, Del Vecchio M, Di Nicola M. Anticancer innovative therapy: Highlights from the ninth annual meeting. Cytokine Growth Factor Rev 2020;51:1-9. [PMID: 31862236 DOI: 10.1016/j.cytogfr.2019.12.002] [Reference Citation Analysis]
14 Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, de Braud F, Di Nicola M, Tagliabue E, Castagnoli L, Pupa SM. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. Cell Oncol 2019;42:815-28. [DOI: 10.1007/s13402-019-00464-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
15 Castagnoli L, Ladomery M, Tagliabue E, Pupa SM. The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers? Cancers (Basel) 2019;11:E902. [PMID: 31261614 DOI: 10.3390/cancers11070902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
16 Collins DM, Conlon NT, Kannan S, Verma CS, Eli LD, Lalani AS, Crown J. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer. Cancers (Basel) 2019;11:E737. [PMID: 31141894 DOI: 10.3390/cancers11060737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 34] [Article Influence: 7.7] [Reference Citation Analysis]